BioSyent Inc.

BioSyent Inc. is a Canadian specialty healthcare company that sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and select international markets. The company's mission is to supply innovative and cost-effective prescription medications that meet the needs of physicians and their patients, with a vision to be a respected global healthcare leader. BioSyent Inc. is headquartered in Mississauga, Ontario, Canada.

BioSyent markets a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. A key area of focus is iron deficiency management, with its flagship FeraMAX® brand consistently ranked as the #1 recommended over-the-counter iron supplement in Canada for 11 consecutive years. The product portfolio also includes Inofolic® for Polycystic Ovary Syndrome (PCOS), Gelclair® for oncology supportive care, Cathejell® for surface anesthesia and lubrication, RepaGyn® for vaginal health, Proktis-M® for rectal health, Combogesic® for pain and fever, and Tibella®/Tibelia® for hormone replacement therapy. Additionally, the company maintains a legacy business marketing non-chemical insecticides through its subsidiary Hedley Technologies Ltd.

René C. Goehrum serves as the President and Chief Executive Officer of BioSyent Inc. The company has demonstrated consistent financial performance, reporting 62 consecutive profitable quarters as of Q4 2025. A significant recent development was the acquisition of Oral Science Inc. in March 2026, which expanded BioSyent's presence into specialized dental hygiene and oral health products. BioSyent's strategy emphasizes commercializing innovative products sourced through international partnerships and a commitment to expanding its pharmaceutical portfolio and accelerating its product pipeline.